CombiChem Appoints Michael G. Rusnak to the Position of Vice President, Business Development.SAN DIEGO--(BW HealthWire)--April 26, 1999-- CombiChem Inc. (Nasdaq NMS See NetWare Management System. :CCHM CCHM Century Campus Housing Management CCHM Cherokee County Historical Museum CCHM CombiChem Inc (stock symbol) CCHM Centre Culturel Haut-Marnais (French) CCHM Certificate in Chinese Herbal Medicine ) announced today that it has appointed Michael G. Rusnak to the position of Vice President, Business Development. Rusnak joins CombiChem in its Palo Alto Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif., office. "Mr. Rusnak's addition to the commercial development team underscores CombiChem's commitment to expanding its drug discovery services business," stated Lee R. McCracken, senior vice president, corporate development/new business ventures. Prior to joining CombiChem, Rusnak served as vice president of marketing and business development at Lexicon Genetics Inc. where he was responsible for both corporate and business development and was instrumental in establishing Lexicon's multi-million dollar genomics collaborations. Previously, Rusnak served in a variety of sales, marketing and project management positions with Aprogenex, Baxter Healthcare, Bayer, Cetus, and BioRad Laboratories. Rusnak earned his B.S. degree in microbiology from St. Bonaventure University Students and alumni refer to the university with an affectionate nickname—"Bona's"—which originates from the school's original name, St. Bonaventure's College. Location The campus sits on 1,200 acres (4. and M.S. degree in clinical science and laboratory management from San Francisco State University • • [ . CombiChem Inc., based in San Diego, is a computational discovery company that is applying its proprietary design technology and rapid synthesis capabilities to accelerate the discovery process for new drugs and chemical products. The company believes its approach offers the pharmaceutical and chemical industries the opportunity to conduct their discovery efforts in a more productive and cost effective manner. Using its proprietary Discovery Engine(TM) process, CombiChem focuses on the generation, evolution, and optimization of new lead candidates for its collaborative partners, who will then develop, manufacture, market, and sell the resulting products. CombiChem has established collaborative agreements with Athena Neuroscience Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Elan Corp., plc., ICOS Corp., ImClone Systems Inc., Novartis Crop Protection AG, Ono Pharmaceutical, Co. Ltd., Roche Bioscience, Sumitomo Pharmaceuticals Co. Ltd. and Teijin Limited. Additionally, CombiChem has established a 50%-owned joint venture with Chirotech Technology Limited, a member of the Chiroscience Group of companies. The joint venture, ChiroChem Discovery Services LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , was created to develop and market computationally designed libraries of single-isomer, chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral compounds to the pharmaceutical industry. CombiChem's press releases are on the Web at www.combichem.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion